A temporary logo

Nineteen Twenty-One

Led by Fredrik Debong, bringing operator know-how and deep networks to the table via his successful ventures in diabetes care, fintech, and innovation management.

As a serial entrepreneur and angel investor, his work has impacted millions, and Nineteen Twenty-One is leveraging this experience to invest in and support companies realising life changing solutions in areas related to type 1 diabetes.

Profile image of Fredrik Debong in a sexy white t shirt, oh and LOOK at those muscles :
Logo of hi.health. Abusing fintech in health insurance. Founded in 2019
Logo of mysugr.com. Mobile diabetes management making diabetes suck less. Founded in 2011, exited in 2017.
Logo of pioneers.io. Founded in 2010, exited in 2018.
Top 2% of VC Lab Cohort 16

Our Mission

Simple.
Make type 1 diabetes and all it carries with it suck less.
How hard can it be!? :P

How We Achieve It

Invest in life changing, early stage companies making it happen.
Make the companies part of the T1D-community,
and the community part of the companies.
Be the smartest money in T1D.
Work together.

Our Principles

Always bring the community in.
Invest early, fast and globally.
Be lean and transparent.
No squeezing, be a bud.
You help, you get.

Companies We Have Invested In

People We Work With And For

One does not do diabetes alone. One does not help companies on ones own. Our approach to taking on diabetes care challenges, and delivering a return to limited partners, is by working with/in a global network of industry professionals, clinicians, patients, researchers, policymakers, angels, savants, GP's of huge VC funds, bankers, grass root advocates and leaders of global policy organisations. Most of us live with T1D.

Renza Siciblia, Global Access, JDRF, AU/USA
Bastian Hauck, Founder and chief wrangler of #dedoc°
PD Dr. med. Katarina Braune, Charité Berlin, Germany
Dr. Martin Tauschmann, WMU, Austria
Prof. Dr. Othmar Moser, Bayreuth University, Germany
Rayhan A. Lal, MD Assistant Professor of Medicine (Endocrinology) and of Pediatrics (Endocrinology)
Prof. Dr. Marc Breton, UVA, USA
Dr. Howard Zisser, the sage of diabetes technology, USA
Bruce Taylor, former Senior Director Gov Affairs at Dexcom, Director Policy at Roche Diabetes Care US, USA
Antonio Estrella, Health Equity at World Economic Forum
Dr. Sufyan Hussain, Kings College London, UK
Dr. Julia Mader, MUG, Austria
Jeff Hitchcock, Founder and President of Children With Diabetes
Melissa Ford-Holloway, Smart Start Ltd, London, UK
Tim Street, T1D tech critic by night, Quant Trader by day
Kamil Armacky, Finance guy by day, diabetes youtuber by night
Amy Tendrich, Founder and Editor of Diabetes Mine
Dan Taylor, communications and media god who GETS it
Frank Westermann, cofounder and CEO 9am.health, cofounder and x-CEO mySugr
Phil Southerland, diabetes advocate and ceo of Super Sapiens
Leif Bowman, CEO allezhealth.com
Dr. Bernhard Schandl, CTO 9am.health, formerly of mysugr.com, teaching at FH Technikum, Vienna
Clemens Helm, DevAcademy, fullstack developer deluxe
Onno Faber, founder of RareBase. An amazing driven entrepreneur who, like Fred, works on solving his own problems.
Christian Hein, Board Director of SNOMED, formerly VP Digital of Novartis, Director Digital Amgen
Dr. Dietmar Schaffarczyk, Lead Auditor, QSI, Lecturer ETH Zurich
Mag. Martin Schmid, CEO and founder of encotec, AT
Sylvana Sinha, Esq, CEO of Praava Health, Bangladesh
Daniel Hefel, CEO MedNeo
Linus Drop, founder and CEO of Lillian Care, DE
Dr. Jörg Hölzing, CEO CGC Genomics, former SVP Roche Diabetes Care
Andreas Klinger, GP Prototype Capital, founding team & CTO of Product Hunt, VPE of CoinList, Head of Remote at AngelList, and CTO at On Deck
Agate Freimanne, GP of Norrsken Ventures
Tim Jürgens, former VP Roche Diabetes Care, Angel, Partner SeedLink Capital, ES
Tanja Dowe, MD at Angelini Ventures
Christophe Maire, Founder & Managing Partner at Atlantic Labs & FoodLabs
Michael Schuster, founder of Boardroom and…… well he's been a busy guy, check him out :)

And many more <3

Get Investment

We'd be honoured to speak with you, thanks for focusing on our area of passion!

There are a few things to keep in mind, on both our ends, that we hope you understand and mind:

– We invest in companies addressing type 1 diabetes and the stuff that kills us

– It is your company, we are here to help you grow it like crazy

– We buy our way into being able to help you make decisions

– Some stuff is simply out there, we like that

– We do first money in, up to select series A's

– The fund is not huge

– We invest €200k-1.5M

– We do our first checks in companies during 2025-2027, then only follow on

– We must invest 70% of our capital in EU

– Time is short, an intro through shared friends helps.

– We have not yet raised the whole fund, work in progress

Meet or Speak

If you find this specialist fund focused on T1D looks good, let's meet up.

Before we can go really deep, we also need to make sure that we CAN work together. See we can only invest for accredited, risk aware and sophisticated investors. It's the law.

Nineteen Twenty One

Investing in making diabetes suck less

1921.vc

© 2024 Fredrik Debong

Imprint: Nineteen Twenty GmbH | FN 649344 v; Commercial court: Vienna Commercial Court, Austria

Contact:
Nineteen Twenty GmbH | 649344v
1921 Fund I: 1921 I EuVECA GmbH & Co. KG | 644756x
Wasagasse 11 / 9
1090 Vienna
Austria

Court of Jurisdiction: Vienna Commercial Court
Email: fred@1921.vc
Phone: +4369911033609
Website: 1921.vc

Privacy Policy
At 1921.vc, we take your privacy seriously. We do not use cookies or tracking technologies on our website. Any personal data you provide (e.g., through contact forms) will be handled in compliance with the General Data Protection Regulation (GDPR).

We collect and process:
- Name and contact details (if you submit them via forms).
- Email addresses for communication purposes.

Your data will not be shared with third parties unless required by law. You have the right to request access, correction, or deletion of your data at any time by contacting us at fred@1921.vc.

Terms of Service
Welcome to 1921.vc. By using our website, you agree to the following terms:
- The content provided on this site is for informational purposes only and does not constitute financial or investment advice.
- You may not copy, reproduce, or distribute any content from this site without permission.
- We reserve the right to modify these terms at any time.

For any questions regarding the use of this website, please contact us at fred@1921.vc

Third Party Tools

We use pagy.co to build and maintain our super simple website. Built by this guy Manny and he seems a nice chap ;) Oh and as no sensitive information is requested by us we are fine with this service built by one guy simply not stating much about how they handle things, and will assume you are too. We're in touch to help him rectify this, but give the guy a break, for now.

For further details, please reach out to our Data Protection Officer, fred@1921.vc.

Cookie Disclaimer

We… don't use cookies. We simply are not good at baking, or see the need of them on this site.
But if you REALLY want a disclaimer, please write one on a postit and slap it on your screen :)

Disclaimer
1921 VC is an EUVECA-registered venture capital fund operating under the European Venture Capital Fund (EUVECA) Regulation (EU) No. 345/2013. The information provided on this website is intended exclusively for professional investors as defined under Directive 2014/65/EU (MiFID II) and other eligible investors who meet the requirements of the EUVECA framework.

No Public Offering
The content on this website does not constitute an offer to sell or a solicitation to invest in any jurisdiction where such an offer or solicitation would be unlawful. This website is provided for informational purposes only and should not be construed as investment, legal, or tax advice.

Investor Eligibility
Investment opportunities offered by 1921 VC are not open to the general public and are restricted to:
✅ Professional investors, including institutional investors, family offices, and asset managers
✅ High-net-worth individuals (HNWIs) who commit a minimum of €100,000 and acknowledge the associated risks
✅ Other eligible investors as defined by the EuVECA regulation

Risk Warning
Investing in venture capital involves a high degree of risk, including the risk of total loss of capital. Past performance is not indicative of future results. Prospective investors should consult their own financial, legal, and tax advisors before making an investment decision.

By visiting this page, you confirm that:
✅ You are a professional investor or an eligible investor under EUVECA rules
✅ You understand the risks associated with venture capital investments
✅ You acknowledge that this website does not constitute an investment offer
OR
✅ You were asked for feedback on the page!